Compass Therapeutics, Inc. (CMPX)

The past six months have seen volatility in Compass Therapeutics' stock price, largely influenced by clinical trial results. On April 27, 2026, shares plummeted after mixed results from the COMPANION-002 Phase 2/3 study of tovecimig in biliary tract cancer, which led to analyst downgrades and a law firm investigation. On May 5, 2026, the company reported its first-quarter 2026 results, highlighting positive Phase 2/3 data for tovecimig in BTC, its Orphan Drug Designation, and plans for a BLA submission later in 2026. On March 5, 2026, the company reported full 2025 financial results and provided a business update, noting that tovecimig successfully met the primary endpoint of overall response rate in the COMPANION-002 study.

The demand for Compass Therapeutics' products and services is not subject to typical seasonal fluctuations. Instead, demand is driven by factors such as the prevalence of the diseases it aims to treat, the progress and success of its clinical trials, regulatory approvals, and the unmet medical needs in the oncology space.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company that discovers and develops antibody-based therapeutics for human diseases. The company focuses on the relationship between angiogenesis, the immune system, and tumor growth to generate anti-tumor responses across malignancies, leveraging platforms like StitchMabs™ to design bispecific and multifunctional antibodies. Key product candidates include Tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, in Phase 2/3 study for biliary tract cancer and studied in colorectal cancer; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in Phase 1 for NSCLC, TNBC, and Hodgkin Lymphoma; CTX-10726, a tetravalent antibody targeting VEGF-A and PD-1, in Phase 1 for solid tumors; and CTX-471, an agonistic antibody against CD137, with a Phase 2 trial expected for tumors expressing NCAM.

Compass Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States. The company's operations and clinical trials are primarily focused within the United States.

Compass Therapeutics' brand reputation has been significantly impacted by the mixed results of its COMPANION-002 clinical trial for tovecimig in biliary tract cancer. The failure to achieve statistical significance for overall survival, coupled with a high crossover rate in the control arm, led to a substantial drop in stock price, analyst downgrades, and an investigation by a law firm into potential securities law violations.

Compass Therapeutics, Inc. is primarily owned by institutional shareholders, who hold 91.12% of the company, while insiders own 22.90%. Major institutional owners include Tang Capital Management LLC, Orbimed Advisors LLC, Suvretta Capital Management LLC, Vivo Capital LLC, BlackRock, Inc., The Vanguard Group, Inc., Enavate Sciences GP LLC, Bvf Inc/il and State Street Corp. The largest individual shareholder is Carl L. Gordon, who owns 15.22 million shares, representing 8.45% of the company.